Drug name - Pepaxto

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6992207 ONCOPEPTIDES AB Melphalan derivatives and their use as cancer chemotherapeutic drugs
Jun, 2022

(3 months ago)

EP1290011B1 ONCOPEPTIDES AB Melphalan Derivatives And Their Use As Cancer Chemotherapeutic Drugs
Jun, 2021

(1 year, 3 months ago)

EP1290011A1 ONCOPEPTIDES AB Melphalan Derivatives And Their Use As Cancer Chemotherapeutic Drugs
Jun, 2021

(1 year, 3 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10543274 ONCOPEPTIDES AB Lyophilized preparation of cytotoxic dipeptides Apr, 2032

(9 years from now)

US10322182 ONCOPEPTIDES AB Lyophilized preparation of cytotoxic dipeptides Apr, 2032

(9 years from now)

US10869928 ONCOPEPTIDES AB Lyophilized preparation of cytotoxic dipeptides Apr, 2032

(9 years from now)

US10285946 ONCOPEPTIDES AB Lyophilized preparations of melphalan flufenamide Apr, 2032

(9 years from now)

Drugs and Companies using MELPHALAN FLUFENAMIDE HYDROCHLORIDE ingredient

Treatment: In combination with dexamethasone to treat relapsed or refactory multiple myeloma (refactory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-cd38 mab) in adults who received at least 4 prior lines of therapy

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE/VIAL POWDER;INTRAVENOUS Discontinued

availability in other generic markets.

Click on the highlighted region to filter.